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Abstract
Introduction: Antiretroviral-based HIV prevention, including pre-exposure prophylaxis (PrEP), is expanding in generalized epidemic settings, but additional prevention options are needed for individuals with periodic, high-risk sexual exposures. Non-occupational post-exposure prophylaxis (PEP) is recommended in global guidelines. However, in Africa, awareness of and access
to PEP for sexual exposures are limited. We assessed feasibility, acceptability, uptake and adherence in a pilot study of a
patient-centred PEP programme with options for facility- or community-based service delivery.
Methods: After population-level HIV testing with universal access to PrEP for persons at elevated HIV risk (SEARCH Trial:
NCT01864603), we conducted a pilot PEP study in five rural communities in Kenya and Uganda between December 2018
and May 2019. We assessed barriers to PEP in the population and implemented an intervention to address these barriers,
building on existing in-country PEP protocols. We used community leaders for sensitization. Test kits and medications were
acquired through the Ministry of Health supply chain and healthcare providers based at the Ministry of Health clinics were
trained on PEP delivery. Additional intervention components were (a)PEP availability seven days/week, (b)PEP hotline staffed
by providers and (c)option for out-of-facility medication delivery. We assessed implementation using the Proctor framework
and measured seroconversions via repeat HIV testing. Successful “PEP completion” was defined as self-reported adherence
over four weeks of therapy with post-PEP HIV testing.
Results: Community leaders were able to sensitize and mobilize for PEP. The Ministry of Health supplied test kits and PEP
medications; after training, healthcare providers delivered the 28-day regimen with high completion rates. Among 124 persons
who sought PEP, 66% were female, 24% were ≤25 years and 42% were fisherfolk. Of these, 20% reported exposure with a
serodifferent partner, 72% with a new or existing relationship and 7% from transactional sex. 12% of all visits were conducted
at out-of-facility community-based sites; 35% of participants had ≥1 out-of-facility visit. No serious adverse events were
reported. Overall, 85% met the definition of PEP completion. There were no HIV seroconversions.
Conclusions: Among individuals with elevated-risk exposures in rural East African communities, patient-centred PEP was feasible, acceptable and provides a promising addition to the current prevention toolkit.
Keywords: post-exposure prophylaxis (PEP); pre-exposure prophylaxis (PrEP); HIV prevention; implementation; uptake; high-risk
exposure
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1 | INTRODUCTION
HIV post-exposure prophylaxis (PEP), the use of antiretroviral medications for 28 days to prevent HIV acquisition after
high-risk exposure, has long been available, and is recommended in World Health Organization guidelines [1,2]. However, it has not routinely been integrated in the prevention
toolkit in sub-Saharan Africa (SSA) beyond limited use
restricted to occupational risks among healthcare workers,
female sex workers and men who have sex with men [3,4].

Some reasons for PEP underutilization include widespread
unawareness of this prevention option, fear of misuse limiting offers of PEP, lack of provider training in screening for
eligible candidates and stigma and discrimination against
high-risk groups such as sex workers and men who have
sex with men [3,5,6,7]. Pre-exposure prophylaxis (PrEP) is
increasing, but not reaching all populations at risk, thus
additional prevention measures are needed [8,9]. We therefore sought to assess feasibility, acceptability, uptake and
adherence in rural Kenyan and Ugandan settings in a pilot
1
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study of a patient-centred PEP programme with options for
facility- or community-based service delivery.

2 | METHODS
2.1 | Study setting
Between December 2018 and May 2019, we conducted a
pilot study of PEP delivery for high-risk HIV exposures in five
rural communities in Kenya and Uganda within the SEARCH
HIV test-and treat trial described previously (NCT01864603)
[10]. The study offered universal access to PrEP during population-level HIV testing to persons at elevated HIV risk (based
on serodifferent partnership, an empiric risk score or selfassessment of risk [11,12]. In five study communities, we conducted PEP pilot to provide an additional prevention option
following elevated-risk HIV exposures.

2.3 | Implementation evaluation framework
We applied a modified version of the implementation evaluation framework proposed by Proctor et al. []. We defined four
levels at which the PEP delivery intervention was designed to
act, and for each, defined the actor (the target of the implementation intervention), the action (the implementation intervention), the target (the goal to be accomplished by the
action), the measures used to assess fidelity (defined as
whether the intervention was executed as planned) and the
measures used to assess the implementation outcome
(whether the intervention achieved its desired goal) (Table 1).
The four levels at which the intervention was designed to act
were (i) the community and opinion leaders, (ii) the healthcare
providers, (iii) the Ministry of Health and clinics and (iv) the
clients receiving PEP.

2.4 | Population and measures
2.2 | Study procedures
We assessed barriers to PEP within the study communities
using focus groups with community members and healthcare
providers in order to inform PEP intervention implementation. Our assessment of barriers to PEP uptake identified
the following: 1) lack of community awareness about PEP as
a prevention option including where to access the services;
2) lack of health system level requests for PEP drugs and
HIV test kits to accommodate PEP beyond occupational
exposure, and lack of flexibility in visit hours and location of
service delivery for PEP; 3) lack of confidence among
healthcare providers to prescribe and deliver PEP to the
general population and, 4) concerns among clients regarding
lack of confidentiality, side effects and lack of access to
trained healthcare providers to answer client questions
around PEP.
We then designed and implemented a multi-component
intervention to address these barriers, building on existing
in-country PEP protocols [13,14]. (1) Community sensitization and mobilization around HIV prevention and the role
of PEP was conducted using community leaders. (2)
Healthcare providers were trained on screening for eligible
participants, 28-day antiretroviral-PEP regimen administration and participant monitoring. Patient-centred service
provision and confidentiality were emphasized. (3) Requisition for supplies such as antiretrovirals and HIV test kits
for PEP delivery were made through the usual Ministry of
Health mechanisms. (4) Participants presenting themselves
at study clinics for PEP were screened. Those found eligible were tested at baseline using country standard antibody-based HIV testing, and if negative, were initiated on
PEP with follow-up visits either in person or via phone
call at week 2 and a HIV test at week 4, 12 and 24. As
per country guidelines, PEP regimens initially comprised
atazanavir/ritonavir, lamivudine, tenofovir (ATV/r/3TC/TDF)
and later, dolutegravir (DTG/3TC/TDF). Participants were
counselled around HIV prevention at the study visits. Our
PEP delivery pilot also comprised; (a) PEP availability
seven days/week, (b) PEP mobile phone hotline (text or
voice) staffed by providers, (c) option for out-of-facility
community-based medication delivery and (d) condom dispensation at study visits.

PEP uptake was defined as enrolment into the pilot with
receipt of a 28-day course of antiretroviral drugs for PEP. We
measured adherence by self-report using three-day recall.
Adverse events in the pilot were measured using DAIDS scale
[16]. Successful “PEP completion” was defined as self-reported
adherence over four weeks of therapy with post-PEP HIV
testing. We evaluated the proportions of participants who initiated PEP, were retained in the study, self-reported adherence to PEP and received HIV testing at week 4, 12 and 24.

3 | RESULTS
3.1 | Fidelity outcomes
Twelve community leaders comprising religious and administrative leaders from the five communities were identified and
sensitized on PEP as an HIV prevention option. Four community meetings per clinic were attended by healthcare providers to train and sensitize the community leadership. Fifteen
healthcare providers comprising seven clinical officers and
eight nurses from six clinics were trained on the PEP delivery
intervention at their respective clinics. The requisition for supply for drugs and test kits was made monthly through the
Ministry of Health with monthly reports of commodities consumed being submitted through the health facility leadership.

3.2 | Implementation outcomes
The community religious and administrative leaders demonstrated a good understanding of PEP as an HIV prevention
option in high-HIV prevalence settings and participated in successful sensitization and mobilization of the communities
(Table 1). The governments through the Ministries of Health
availed supplies on request such as antiretrovirals for PEP,
HIV test kits and national treatment guidelines for reference.
Healthcare providers in the PEP delivery clinics were trained
on delivery of PEP to those reporting high-HIV risk exposures.
The providers were able to assess risk, conduct HIV testing
and initiate eligible participants on PEP. They conducted follow-up for up to 24 weeks while assessing adherence by selfreport for the duration participants were on PEP. Visits were
conducted at clinics or out-of-facility based on participants’
2
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Table 1. Feasibility metrics and outcomes during the conduct of the PEP delivery pilot in five rural communities in Uganda and
Kenya
Actor: Who are
you trying to act

Fidelity Measurement:

Implementation Outcome:

Action: Implementation

Target: What are you trying to

Was intervention

Did it accomplish intended

intervention

accomplish with action?

done as planned?

goal?

on?
Community

Train community leaders on

leaders

PEP in the community

Ministry of
health

Make commodity request for

Understand concept of PEP and

Two meetings every

Community leaders

explain to the community

month held with

participated in

situations in which PEP would

community leaders in

sensitization of the

be indicated

each community for
two months

community of PEP as a
HIV prevention option

Ensure availability of PEP

made using the

medications availed and

timely manner to ensure

at clinics

existing supply

dispensed over the period

Obtain guideline booklets on
PEP (regimen, adverse

Ensure guidelines on PEP for
reference are available for
healthcare workers

Train health providers on

requisition system

of the pilot study

and commodities

No stock outs of PEP

supplied

events) for providers

providers

158 bottles of regimen

medications and HIV test kits

uninterrupted supply

Healthcare

Commodity requests

test kits and medication in a

Enhance competence and ability

occurred during the study

Treatment guidelines
availed in all clinics

period
343 HIV test kits used

Trainings on PEP

All health providers engaged

identifying eligible

of healthcare providers to offer

delivery conducted

(n = 15) were able to

participants for PEP and

PEP to participants and conduct

for healthcare

offer PEP to willing

offering PEP in a high HIV

structured follow-up visits

providers at all

prevalence setting, including

including HIV tests

targeted clinics

participants
All 15 providers dispensed

patient confidentiality and

PEP to at least one

patient education on side
effects

participant during the
study

Train health providers on

Providers completed 267

structured follow-up visits

follow-up visits for

designed to enhance

participants

adherence and regimen
completion
Client/community

Offer PEP to eligible
participants

Enhance PEP uptake and
adherence to medication and
follow-up visits

PEP availed and

124 participants were

offered at all clinics
for those willing to

enrolled and started on
PEP with 88% reporting

initiate PEP and

adherence and 97% being

follow-up visits

retained at four weeks

conducted

preference. Providers were also able to reach participants on
phone to monitor their progress, assess adherence and
address any concerns such as side effects.
Community members with high-HIV risk exposures willingly
presented themselves to clinics offering PEP for clinicianassessment and PEP initiation where applicable.

3.3 | Uptake of PEP
A total of 124 participants were initiated on PEP in our pilot;
84 (68%) were from Kenya; 82 (66%) were male. Two-thirds
of the participants were aged between 15 and 35 years; 30
(24%) were ≤25 years; 52 (42%) were aged 25 to 34 years.
71 (58%) were married; 8 (7%) in polygamous marriages and
46 (37%) reported being single. Sixty-six (54%) were in occupations associated with higher HIV-risk, most of these, 52
(42%) being fisherfolk. Among all participants, 91 (73%) were

initiated on DTG/3TC/TDF, whereas the rest were initiated
on an Atazanavir/ritonavir-based regimen.
Among those who were enrolled in the pilot, various reasons were reported for initiating PEP. 83 (67%) were in new
or existing relationships with partners who they suspected to
be HIV infected. Of note, 14 (11%) of the sexual partners
feared to be infected were reported as fisherfolk. Additionally,
17 (14%) reported unplanned sexual exposure with a serodifferent spouse, 10 (8%) from transactional sex, 6 (5%) from
sexual intercourse with a known HIV-infected person and 2
(2%) from non-consensual sex.

3.4 | PEP visits, adherence and retention
Twelve percent of all visits were conducted at out-of-facility
community locations; 43 (35%) of participants had ≥1 off-site
visit. 120 (97%) of participants were retained at a four-week
3
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PEP retenƟon, adherence and HIV tesƟng (n=124)
100%
100%

99%

98%

97%

95%

95%
88%

90%
80%
70%
60%
50%
40%
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30%
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0%

0%
Week 1

Week 2
Retained

Adherent

Week 4
HIV Tested

Figure 1. PEP retention, adherence and HIV testing during the course of the pilot.(Retention: Visit attendance at week 1, 2 and 4, Adherence: Use of PrEP measured by self-report using three-day recall, HIV Tested: Proportion receiving a HIV test at specified week 4 study
visit).

follow-up with 109 (88%) reporting adherence over all followup visits (Figure 1). Overall, 105 (85%) met the definition of
PEP completion. 118 (95%) received HIV testing at week 4
follow-up, 88% at week 12 and 83% at week 24. There were
no HIV seroconversions.

3.5 | Adverse events
No serious adverse events were reported. Two participants
reported mild dizziness, two experienced mild generalized
body malaise, one receiving atazanavir had grade two jaundice
and one reported mild nausea. All events resolved spontaneously without having to stop PEP.

4 | DISCUSSION
Our study demonstrates feasibility of PEP as an HIV prevention option among the general population in rural sub-Saharan
Africa settings with high HIV prevalence. To our knowledge,
this is the first documented study to target the general population in rural SSA with PEP for HIV prevention. In this pilot
study, we found high retention and adherence to the 28-day
PEP regimen. Unlike other studies that have focused on evaluating PEP in known high-risk groups such as sex workers and
MSM [3,6], we offered PEP to the general population within a
high HIV prevalence setting. In these settings, individuals may
not necessarily be on an ongoing continuous high-risk exposure that would warrant PrEP [2]. However, they may experience sporadic or occasional unplanned episodes of high-risk
exposures that may end in infection. Judicious PEP use may
be the prevention option of choice that will suppress new
infections among this subgroup of the population. PEP as
delivered in this pilot was shown to be safe and tolerable with
no seroconversions observed.
PrEP has been shown to have high efficacy in randomized
controlled trials among persons with high and sustained
adherence [17]. However, many at risk either do not initiate
PrEP when offered or have difficulties sustaining use over
time [8,18,19]. Barriers to PrEP use include not feeling at risk,

change in risk over time with the inability to anticipate or control, difficulties taking daily medication over a prolonged period, as well as stigma and fears of disclosure [18,19]. PEP
offers a complementary prevention measure to PrEP that
addresses barriers such as unplanned episodes of high-risk
exposure, and shorter duration of use during a period when
individuals are highly motivated to sustain use. Furthermore,
PEP may provide a bridge to PrEP initiation or reengagement
for some individuals; this potential merits further study in this
context, including improved understanding of risk perception
as a barrier to PrEP..
Components of our intervention designed to address barriers to PEP use reveal the need for a client-centred approach.
The high retention and adherence observed may be attributed
to the flexibility in visit hours, choice of visit locations as well
as phone access to a healthcare provider whenever required.
One-third of our participants opted for community-based visits at least once in the course of follow-up, demonstrating the
value of flexibility and the potential to improve retention
among enrolees in prevention interventions.
Limitations of our study include self-report of PEP adherence which is subject to social desirability bias. However, no
participants seroconverted during the trial, suggesting adequate drug levels to prevent infection. Second, our sample
size was small and therefore meaningful comparison of data
stratified by gender or region could not be carried out.
Finally, the study started with protease inhibitor regimens
(27% of clients), no longer the standard-of-care; however,
current integrase inhibitor-based regimens are more tolerable and would be expected to better facilitate uptake and
adherence.
As an implementation outcome in the model proposed by
Proctor et al.[15], sustainability is crucial. The existing commodity supply chain, healthcare staffing and community sensitization strategy have the capability to initiate PEP
programmes and further improve the uptake of this prevention option. It will be important to do a formal cost analysis to
inform scalability of this intervention. This set up could ensure
long-term viability by integrating the programme within existing policies and practices [20].

4
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5 | CONCLUSIONS
Among persons with high-risk HIV exposures in a high prevalence, rural East African setting, a patient-centred PEP programme was feasible, acceptable and provides a promising
addition to the current prevention armamentarium.
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